These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27486568)

  • 1. Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study.
    Wilke T; Mueller S; Groth A; Berg B; Hammar N; Tsai K; Fuchs A; Stephens S; Maywald U
    J Diabetes Metab Disord; 2015; 15():28. PubMed ID: 27486568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
    Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.
    Strongman H; D'Oca K; Langerman H; Das R
    Diabetes Obes Metab; 2015 Jun; 17(6):573-580. PubMed ID: 25735201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
    Losada E; Soldevila B; Ali MS; Martínez-Laguna D; Nogués X; Puig-Domingo M; Díez-Pérez A; Mauricio D; Prieto-Alhambra D
    Osteoporos Int; 2018 Sep; 29(9):2079-2086. PubMed ID: 29860664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes.
    Ioacara S; Guja C; Reghina A; Martin S; Sirbu A; Fica S
    Endocr Res; 2018 May; 43(2):97-105. PubMed ID: 29308936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.
    Gautam S; Agiro A; Barron J; Power T; Weisman H; White J
    Cardiovasc Diabetol; 2017 Jul; 16(1):93. PubMed ID: 28756774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors
    Roberto G; Girardi A; Barone-Adesi F; Pecere A; Ientile V; Bartolini C; Da Cas R; Spila-Alegiani S; Ferrajolo C; Francesconi P; Trifirò G; Poluzzi E; Baccetti F; Gini R
    Front Pharmacol; 2022; 13():871052. PubMed ID: 35707398
    [No Abstract]   [Full Text] [Related]  

  • 12. Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR).
    Ekström N; Svensson AM; Miftaraj M; Andersson Sundell K; Cederholm J; Zethelius B; Eliasson B; Gudbjörnsdottir S
    BMJ Open Diabetes Res Care; 2015; 3(1):e000059. PubMed ID: 25815205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy.
    Lorenzoni V; Baccetti F; Genovese S; Torre E; Turchetti G
    Clinicoecon Outcomes Res; 2017; 9():699-710. PubMed ID: 29200879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of combined therapy for type 2 diabetes.
    Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J
    Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study.
    Holden SE; Jenkins-Jones S; Currie CJ
    PLoS One; 2016; 11(5):e0153594. PubMed ID: 27152598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription of Sulphonylureas among Patients with Type 2 Diabetes Mellitus in Italy: Results from the Retrospective, Observational Multicentre Cross-Sectional SUSCIPE (Sulphonyl_UreaS_Correct_Internal_Prescription_Evaluation) Study.
    Giorda CB; Orsi E; De Cosmo S; Bossi AC; Guerzoni C; Cercone S; Gilio B; Cavalot F
    Diabetes Ther; 2020 Sep; 11(9):2105-2119. PubMed ID: 32734558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis.
    Jeon WK; Kang J; Kim HS; Park KW
    J Lipid Atheroscler; 2021 May; 10(2):210-222. PubMed ID: 34095013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.